Piper Sandler analyst Do Kim maintained a Buy rating on Codexis (CDXS – Research Report) on January 18 and set a price target of $10.00. The company’s shares opened today at $2.72.
According to TipRanks, Kim is ranked #1736 out of 8601 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Codexis with a $6.75 average price target, a 148.16% upside from current levels. In a report released on January 17, Craig-Hallum also maintained a Buy rating on the stock with a $9.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Codexis’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $9.28 million and a GAAP net loss of $34.91 million. In comparison, last year the company earned a revenue of $34.47 million and had a GAAP net loss of $9.99 million
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CDXS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Codexis (CDXS) Company Description:
Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Read More on CDXS:
- Codexis price target raised to $3 from $2 at TD Cowen
- Codexis enters into purchase agreement with Nestle Health Science for CDX-7108
- Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
- Codexis enters into pruchase agreement with Nestle Health Science for CDX-7108
- Codexis and Aldevron in licensing pact for Codex HiCap RNA Polymerase
